Vig K., Tiwari P., Parveen A., Rangari V., Singh S.R.
Alabama State University, US
Keywords: 4T1 cells, doxorubicin, superparamagnetic iron oxide nanoparticles
The present study investigates the development of superparamagnetic iron oxide nanoparticles as a controlled release drug formulation and use as anticancer therapeutic agents. Iron oxide nanoparticles (IONPs) were synthesized using ultrasonic irradiation of iron pentacarbonyl in the presence of Poly Vinyl Alcohol (PVA). Further crystal growth of IONPs was carried out using IONPs as a seed along with PVA and ethylenediamine. Three nanoparticles (NP1, NP2, NP3), superparamagnetic and highly porous were prepared ranging between 10-50 nm in size. NP3 (50 nm) were then loaded with doxorubicin. Drug release assay showed 50% of doxorubicin release from NP3 in 24 h, with no further release upto 96 h indicating slow release of drug to the targeted tissues. The nanoparticles (NP1, NP2, NP3) were tested for their toxicity (0-250 ug /ml) to human cells, HEp-2 using MTT assay. 90% cell viability was observed even at 250 µg/ml concentrations. NP3 and drug loaded NP3 were tested to kill mammary tumor 4T1 cells. 50% cell viability of 4T1 cells was observed at 75 and 150 µg/ml with NP3 and drug-loaded NP3 respectively. Present study shows IONPs as a good drug delivery agent against cancer cells with low toxicity towards normal healthy cells.
Journal: TechConnect Briefs
Volume: 3, Nanotechnology 2012: Bio Sensors, Instruments, Medical, Environment and Energy (Volume 3)
Published: June 18, 2012
Pages: 234 - 237
Industry sectors: Advanced Materials & Manufacturing | Medical & Biotech
Topics: Biomaterials, Cancer Nanotechnology
ISBN: 978-1-4665-6276-9